The analysis deduced that tumor samples from patients in the low-risk group were more likely to exhibit favorable immune responses to PD-1/PD-L1 or CTLA4 inhibitors, or a combination thereof (Figure 8C). This evidence concerns the gene CTLA4 and neoplasm.